EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Arcutis Biotherapeutics's enterprise value is $938.90 Mil.
Arcutis Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-227.86 Mil. Therefore, Arcutis Biotherapeutics's EV-to-EBITDA for today is -4.12.
The historical rank and industry rank for Arcutis Biotherapeutics's EV-to-EBITDA or its related term are showing as below:
ARQT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.51 Med: -1.89 Max: -0.41
Current: -4.12
During the past 7 years, the highest EV-to-EBITDA of Arcutis Biotherapeutics was -0.41. The lowest was -4.51. And the median was -1.89.
ARQT's EV-to-EBITDA is ranked worse than 100% of 473
companies
in the Biotechnology industry
Industry Median: 9.22
vs ARQT: -4.12
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-25), Arcutis Biotherapeutics's stock price is $8.75.
Arcutis Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.920. Therefore, Arcutis Biotherapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Arcutis Biotherapeutics EV-to-EBITDA Historical Data
The historical data trend for Arcutis Biotherapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Arcutis Biotherapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Arcutis Biotherapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcutis Biotherapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Arcutis Biotherapeutics's EV-to-EBITDA falls into.
Arcutis Biotherapeutics EV-to-EBITDA Calculation
Arcutis Biotherapeutics's EV-to-EBITDA for today is calculated as:
Arcutis Biotherapeutics's current Enterprise Value is $938.90 Mil.
Arcutis Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-227.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Arcutis Biotherapeutics's PE Ratio for today is calculated as:
Arcutis Biotherapeutics's share price for today is $8.75.
Arcutis Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.920.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Arcutis Biotherapeutics EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Arcutis Biotherapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Arcutis Biotherapeutics (Arcutis Biotherapeutics) Business Description
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARQT has been successfully added to your 